ABSTRACT
Lysosomes are emerging as important players in cellular zinc ion (Zn 2+ ) homeostasis. The series of work on Zn 2+ accumulation in the neuronal lysosomes and the mounting evidence on the role of lysosomal Zn 2+ in cell death during mammary gland involution set a biological precedent for the central role of the lysosomes in cellular Zn 2+ handling. Such a role appears to involve cytoprotection on the one hand, and cell death on the other. The recent series of work began to identify the molecular determinants of the lysosomal Zn 2+ handling. In addition to zinc transporters (ZnT) of the solute-carrier family type 30A (SLC30A), the lysosomal ion channel TRPML1 and the poorly understood novel transporter TMEM163 have been shown to play a role in the Zn 2+ uptake by the lysosomes. In this review, we summarize the current knowledge on molecular determinants of the lysosomal Zn 2+ handling, uptake, and release pathways, as well as discuss their possible roles in health and disease.
INTRODUCTION
The central paradigm of Zn 2+ handling involves its entry in cells via the plasma membrane transporters, chelation by the cytoplasmic proteins, and export into membrane-bound organelles via dedicated transporters (1) (2) (3) (4) . As commonly known, such organelles include components of the Golgi network, mitochondria, and the "secretory vesicles." The observations in neuronal cells, in breast tissue, and in certain model system points out that lysosomes are also involved in the Zn 2+ handling. Such evidence is based on Zn 2+ accumulation in the lysosomes of cells exposed to Zn 2+ , or in cells undergoing processes associated with large Zn 2+ transitions, such as cell death at the onset of mammary gland involution and pathological events (5-11). The lysosomal involvement in Zn 2+ handling is interesting from several perspectives. First, it redefines the role of the lysosomes as purely digestive organelles. Second, it uncovers some interesting new biology pertaining to cell death and survival, especially in tissues in which the lysosomal involvement has been underappreciated. Third, it shows the involvement of new regulatory circuits involving energy sensing, oxidative stress, and organellar biogenesis.
Zn
2+ enters the lysosomes through endocytosis of Zn 2+ -bound proteins, autophagy of Zn 2+ -rich organelles, and from the cytoplasm via the zinc transporters located in the lysosomal membrane. Proteomic analysis of the lysosomal membrane suggested the presence of ZnT2 and ZnT4 transporters, which was confirmed using confocal microscopy and knockdown studies in several systems (10, (12) (13) (14) . Another pathway, a "maturation" of Zn 2+ -rich secretory granules into the lysosomes has been shown in the mammary gland; the presence of such a process in other tissues remains to be an interesting question (11, 15, 16) . Whereas the Zn 2+ entry into the lysosomes via endocytosis and autophagy appears to be a normal consequence of the lysosomal digestive function, its uptake from the cytoplasm into lysosomes is an emerging role for these organelles. Based on this evidence, we proposed a concept of the lysosomal Zn 2+ sink, a process of absorption of Zn 2+ from the cytoplasm into the lysosomes. This process could be especially important during abrupt changes in the cytoplasmic concentration of Zn 2+ , as it would give the cells time to update their Zn 2+ chelation and extraction capacities (8) (Figure 1 ). © 1996-2017
An extremely attractive aspect of the lysosomal biology that sets it apart from the Golgi as a Zn 2+ sink is its dynamic regulation by the recently discovered lysosomal gene network. Such a network regulated by transcription factor EB (TFEB), and its relatives TFE3 (transcription factor binding IGHM enhancer 3) and MITF2 (microphthalmia-associated transcription factor 2) was shows to relay the information from mechanistic target-of-rapamycin (mTORC1) to transcriptional activity of a number of genes coding for the lysosomal and autophagic proteins (17) . Since mTORC1 is a signaling nexus responsible or gauging the cellular energy and the functional status of the lysosomes, a possible role of the lysosomes as a cellular Zn 2+ clearance pathway casts a new light on these organelles as key players (18, 19) . Indeed, if the lysosomes are a powerful transition metal buffering and extraction pathway, as was recently proposed, then perhaps the definition of the lysosomes and the lysosomal gene network might be amended to include the oxidative stress response element. The recent evidence that the lysosomal biogenesis is stimulated by the transition metal exposure supports this idea (20) .
The growing knowledge of the lysosomal role in Zn 2+ handling coincides with the discovery of the lysosomal exocytosis and lysosomal biogenesis as driving factors in cellular detoxification. Upregulation of the lysosomal biogenesis stimulated by the TFEB overexpression has been linked to improving cellular phenotypes in in vitro models of several diseases including Pompe, Alzheimer's, Parkinson's, Huntington's, and hepatic SERPINA1 deficiency (21) (22) (23) (24) (25) . Such an improvement has been linked to increased removal of the storage bodies and misfolded protein aggregates. Lysosomal exocytosis has been proposed as a driving force behind such an improvement (22, 26) . It is thus telling that TFEB overexpression and increased lysosomal exocytosis have been linked to improved removal of copper ions (Cu 2+ ) and Zn 2+ , and suppressed oxidative stress in cells exposed to these metals (20, 27) . On the contrary, suppression of the lysosomal exocytosis has been linked to increased oxidative stress in cells treated with Cu 2+ or Zn 2+ . It is important to note that beyond the "lysosomal" genes, the TFEB-responsive network incorporates genes involved in regulation of oxidative stress such as heme oxygenase 1 (HMOX1) (28) . Indeed, the TFEBdependent upregulation of HMOX1 expression has been shown in response to Cu 2+ exposure of cultured cells (20) . To further the argument for the interaction of the lysosomal biogenesis and oxidative stress responses, regulation of the lysosomal biogenesis by FXR-CREB and PPAR transcription factors previously implicated in the oxidative stress responses has been shown (23, (29) (30) (31) . (32) .
A buildup of Zn 2+ in the lysosomes of cells exposed to oxidative stress or high Zn 2+ levels to induce Zn 2+ uptake across the plasma membrane has been shown in various cell culture models using the high affinity dye, Fluozin-3 (5, 6, 9, 33-35). Such buildup has led to lysosomal permeabilization followed by the release of the lysosomal digestive enzymes and cell death by the autophagic scenario. Due to the previous evidence of Zn 2+ buildup in brains affected by stroke and other neurodegenerative diseases, these findings were interpreted as an explanation for cell death in these diseases (36) (37) (38) . According to this model, an excess cytoplasmic Zn 2+ entering the cells at increased rate through the plasma membrane or due to liberation of Zn 2+ from the cytoplasmic Zn 2+ -binding proteins, which floods the cytosol and subsequently, the lysosomes and mitochondria (4, 35, (39) (40) (41) (42) (Figure  1 ). Such a Zn 2+ overload then triggers cell death (43) (44) (45) . Interestingly, a significant increase in cerebral Zn 2+ levels of Mucolipin-1 knockout (Mcoln1 -/-) mice, a model for Mucolipidosis type IV (MLIV), has been reported (5, 6, 9). It was surmised that lysosomal Zn 2+ overload could potentially contribute to MLIV pathology, as well as cause progressive neuronal and retinal cell degeneration (6) . MLIV is a human lysosomal storage disease caused by a loss-of-function mutation or deletion in the Mucolipin-1 (TRPML1) ion channel (46) (47) (48) . TRPML1 confers non-selective permeability to calcium (Ca 2+ ), Zn 2+ , ferrous iron (Fe 2+ ), and manganese ions (Mn 2+ ), suggesting that TRPML1 may function in metal homeostasis (49) (50) (51) (52) . Indeed, Zn 2+ mishandling by the lysosomes in MLIV-affected cells has been revealed consistently, in addition to a previous report that Fe 2+ overload may also be a contributing factor in disease etiology (5, 6, 9, 49 (33, (60) (61) (62) (63) . Despite these observations, the role of the lysosomes in retinal Zn 2+ handling has not been pursued, and in general, there is a dearth of knowledge on the lysosomal function in the retina with respect to lysosomal biogenesis and exocytosis.
The first evidence of Zn 2+ transporters localized to the lysosomal membrane came from mammary gland in which involution at the end of lactation appears to be associated with translocation of the transporter ZnT2 to the lysosomal membrane and a buildup of Zn 2+ in the lysosomes. This is followed by the destabilization of the lysosomal membrane and cell death. In contrast to the neuronal tissue, lysosomal Zn 2+ buildup in the mammary gland appears to be dynamically regulated component of a developmental program. For a complete account of Zn 2+ handling and transporters in the involuting mammary gland, we refer to a recent comprehensive review on this topic by Kelleher and colleagues (15). A confocal analysis of recombinant protein and short interfering RNA (siRNA)-mediated analysis showed that while recombinant ZnT2 and ZnT4 are routed to the lysosomes in HeLa cells, the native ZnT2 does not contribute to the lysosomal Zn 2+ uptake in these cells. Instead, this seems to be a function of ZnT4 in HeLa cells. This is consistent with the previously shown exclusive localization of ZnT2 in the mammary gland tissue and a wider expression of ZnT4 (10). The lysosomal localization of ZnT4 has been confirmed by the recently published lysosomal proteomic analysis (64) . © 1996-2017 While the uptake of Zn 2+ from the cytoplasm into the lysosomes and the resulting buildup and toxicity fits well into the idea of Zn 2+ -mediated cell death under degenerative conditions and during the mammary gland involution, such mechanisms may play a cytoprotective role in other tissues. However, this protective process requires elimination of the lysosomal Zn 2+ at the end of the Zn 2+ spike. Lysosomal exocytosis seems to have emerged as such a defense mechanism (8). Originally proposed as a means of plasma membrane repair, lysosomal exocytosis is now being recognized as a key cellular detoxification and stress repair pathway (65) . Lysosomal exocytosis is driven by the lysosomal fusion with the plasma membrane, mediated by VAMP7 and synaptotagmin 7, and by the cytoplasmic calcium ion (Ca 2+ ) spike (66). The latter was posited to depend on the endolysosomal Ca 2+ release via TRPML1 and TRPML3 ion channels, although its dependence on Ca 2+ entry across the plasma membrane has been shown as well (27, (67) (68) (69) . As previously mentioned, lysosomal exocytosis of storage bodies and unfolded proteins was suggested to underlie the improvement of cellular phenotypes of several diseases (26) . In these experiments, the in vitro disease models were transiently transfected with TFEB cDNA to cause overexpression of this transcription factor and stimulation of the lysosomal exocytosis. The resulting improvement was attributed to the increased lysosomal exocytosis and increased extraction of toxic material. The role of lysosomal exocytosis in the removal of excess (lysosomal) Zn 2+ from cells has been recently shown using siRNAmediated knockdown of VAMP7 and synaptotagmin 7, which resulted in the buildup of Zn 2+ and oxidative stress in Zn 2+ -treated cells (8).
Based on the data summarized in this chapter, a concept of the lysosomal Zn 2+ sink was proposed. We postulated that Zn 2+ uptake into the lysosomes via the lysosomal Zn 2+ transporters quickly lowers the cytoplasmic Zn 2+ levels and gives the cells time to induce expression, modify, and target ionic buffering through various efflux transporters and chelating proteins (Figure 1 ). Such high capacity dynamic system may serve as a first line of defense mechanism against the cytoplasmic Zn 2+ spike -lysosomes occupy 3% to 5% of the cellular volume according to some estimates (70) . Lysosomes are thus able to respond to a wide range of signals and are dynamically regulated by the signaling loop of circuits concerning cell stress (e.g. oxidative stress, lysosomal damage, and starvation). An increase in the cytoplasmic Zn 2+ clearance may serve a cytoprotective role, while such clearance may be decreased when cell death is a desirable outcome. As shown in a recent publication by one of us (KK), the rate of lysosomal exocytosis is a factor defining its cytoprotective role (8). While some molecules involved in the lysosomal exocytosis of Zn 2+ are fairly well understood, some are still poorly understood or just beginning to shed light on their new roles. One of such molecules is discussed in the next chapter.
TMEM163 AND ZINC ACCUMULATION
Transmembrane-163 (TMEM163) protein, also known as synaptic vesicle 31 (SV31), was first identified in rat brain synaptosomes using proteomics (71) . The TMEM163 gene is conserved across many vertebrate species (chimpanzee, Rhesus monkey, cow, dog, chicken, mouse, rat, zebrafish, and frog) and has over 100 orthologues. TMEM163 protein expression is detected in certain glutamatergic and g-aminobutyric acid (GABA)-ergic neuronal populations (71, 72) . Its presence in synaptic-like micro-vesicles, large dense core vesicles, endosomes and lysosomes overlaps with the enrichment of zinc in pre-synaptic vesicles of these neuronal populations (71) (72) (73) . Furthermore, subcellular fractionation of PC12 cell lysates stably expressing the rat Tmem163 also showed that this protein is detected in the plasma membrane, endoplasmic reticulum (ER), Golgi, mitochondria, and peroxisomes (72) .
An interaction between TMEM163 and TRPML1 was recently shown using genetic (yeast two-hybrid) and biochemical (co-immunoprecipitation) assays (5) . The interaction between the two proteins appears to influence intracellular zinc homeostasis, at least in a heterologous expression system using cultured cells (5, 74). Moreover, the expression level of TMEM163 is down-regulated in MLIV patient fibroblasts (5). It is not clear, however, how such a reduction in TMEM163 protein potentially contributes to the disease phenotype. Nevertheless, the tissue mRNA expression pattern of TMEM163 gene coincides well with that of MCOLN1 (TRPML1) gene (5, 75) . Specifically, higher relative TMEM163 transcripts are observed in the brain, lung, and testis, but notable levels are seen also in the pancreas, kidney, thymus, ovary, and intestines ( Figure 2 ). Confocal microscopy of heterologously expressed human TMEM163 shows plasma membrane (PM) and lysosomal localization (Figure 3) . A partial co-localization with TRPML1 is observed, suggesting that both proteins may have specific cellular function that is independent of each other (Figure 3 ). TRPML1 has been reported to have a diLeucine motif (D/E)XXXL(L/I) or lysosomal targeting sequence (LTS) at the N-terminus, while another dileucine motif situated at the C-terminus serves as an internalization signal for adaptor protein 2 (76). Human TMEM163 (or rodent Tmem163) has a putative diLeucine motif (D/E)XXXL(L/I) or lysosomal targeting sequence (LTS) with amino acid residues EDRGLL at its N-terminus position 65-70 ( Figure 4) (5) . The LTS motif is also present on certain Zrt-and Irt-like proteins (ZIP, also known as SLC39A) and ZnT proteins. For © 1996-2017 example, ETRALL is found on ZIP1, DDDSLL on ZnT4, and DAAHLL on ZnT2 or ZnT3 (72-77, 103-110, 144-149). In general, proteins containing a di-Leucine motif are targeted by adaptor proteins for membrane trafficking to and from the plasma membrane, tubular endosomes or endosomal-lysosomal compartment, or Golgi network (77, 78) .
The rodent Tmem163 protein is predicted to have six transmembrane domains with long N-terminus and short C-terminus regions predicted to be cytoplasmic (71, 72) . A closer inspection of human TMEM163's protein sequence (Figure 4) shows an apparent topological similarity with the ZnT proteins, whereby TMEM163 has a predicted long N-terminus but short C-terminus, while the ZnT proteins have a predicted short N-terminus but long C-terminus region. This may be, of course, a mere coincidence; however, we cannot rule out the possibility that TMEM163 may belong to the SLC39A or SLC30A family of influx or efflux transporter proteins, respectively. Further, the tissue specific expression pattern of TMEM163 coincides well with other ZnTs, and thus contributes to transporter redundancy in many cell types (79) (80) (81) (82) . The amino acid sequence alignment of rodent Tmem163 with mouse ZnT3, E. coli zinc transporter (YiiP), and R. metallidurans cobalt-zinc-cadmium resistance protein (CzcD) shows around 20% sequence identity (72) . From the same alignment, two aspartate (D) residues on the predicted second transmembrane (TM) domain were conjectured to potentially bind Zn 2+ . It is interesting to note that Histidine (H) and/or D residues such as the HXXXD motif (where X is a non-polar amino acid) located within TM2 and TM5 helices of ZnT proteins, and HXXXH motif in TM4 and TM5 helices of ZIP proteins have been suggested to facilitate tetrahedral zinc coordination (82, 83) . Collectively, these amino acid residues have been designated as HD-DD motifs present in zinc transport proteins, and site-directed mutagenesis of native HD residues within TM4 and TM5 helices of the ZnT5 protein has been shown to disrupt zinc binding and transport activity (83 The main function of Metallothionein (MT) proteins is to act as a zinc reservoir, and to control the distribution of Zn 2+ to other zinc-binding proteins (84) . However, MT is not a long-term storage for Zn 2+ due to its short biological half-life (85), which necessitates vesicular or compartmental storage of zinc. Specifically, Zn 2+ may be stored in the neuronal synaptic vesicles, endosomes or lysosomes, endoplasmic reticulum (ER)) and mitochondria. Transport of Zn 2+ into or out of these compartments is mediated by ZnTs, ZIPs, and divalent cation transporter protein families (82, 86) . To further investigate the function of Tmem163, rat PC12 cells stably expressing the protein and subsequently exposed to Zn 2+ showed accumulation within vesicular structures and cytoplasmic compartments as evidenced by the zinc-specific dye, Fluozin-3 (72). It was then suggested that rodent Tmem163 protein could be a Zn 2+ efflux transporter. One of us (MPC) has found that cultured SH-SY5Y human neuroblastoma cells heterologously expressing TMEM163 markedly accumulate intracellular zinc following a brief exogenous zinc chloride (ZnCl 2 , 100 mM, 1 hour exposure). A concomitant increase in the relative MT1A transcript expression levels is observed in TMEM163-overexpressing SH-SY5Y neuroblastoma cells compared with controls ( Figure  5 ). This observation suggests that TMEM163 is a novel transporter of Zn 2+ , and is thus critical to 
Zn
2+ homeostasis in specific tissues or organs. Interestingly, it was also observed that heterologously co-expressed TMEM163 and ZnT4 produces intracellular zinc elevation in cultured cells upon exogenous ZnCl 2 (100 mM) exposure as evidenced by Fluozin-3 fluorescence (87) . This finding suggests that TMEM163 and ZnT4 physically interact with each other in distinct cells that express both proteins. In line with this possibility, several ZnT proteins have been reported to interact and form heterodimers with each other (88) (89) (90) (91) . It is worth noting that ZnT2 and ZnT4 heterodimers localize to the plasma membrane, whereas ZnT2 or ZnT4 homodimer each localize to their respective vesicular compartment (89) . It is thus possible that TMEM163 and ZnT4 heterodimers confer distinct function when compared to their respective homodimers. Further work needs to be done in order to prove if TMEM163 is an influx or efflux transporter, and whether it interacts with ZnT4 or other ZnTs, as well as ZIP transporters.
In summary, the lysosomal Zn 2+ handling appears to be a critical period that could mean survival or death upon cytoplasmic Zn 2+ overload in many cell types, especially in neurons. The TRPML1, ZnT4, and TMEM163 proteins may be central to Zn 2+ handling that involves the lysosomes and other membranebound compartments ( Figure 6 ). Future research to define the contributions of these proteins in cellular zinc homeostasis. There are still many gaps in our knowledge regarding the function of TMEM163, and the relevance of its interaction with TRPML1 or its putative interaction with other zinc transporters. For example, does TRPML1 mediate the subcellular trafficking of TMEM163? Does TRPML1 function cooperatively with TMEM163 in terms of releasing cations from the lysosomes into the cytosol according to previous reports suggesting that TRPML1 is a "release" channel? Finally, does the functional loss of TRPML1, which creates hyperacidic and zincelevated lysosomes, confers concomitant inhibition of TMEM163 function? Does TMEM163 belong to a new class of ZnT-or ZIP-like proteins, which could explain its redundant expression pattern with ZnT or ZIP in various tissues? These are just a few questions that must be answered in order to advance the field and fully understand the role of TMEM163 in normal and pathological states. 
